Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

2017 Clinical practice guidelines for dyslipidemia of Korean children and adolescents

  • Received : 2020.08.03
  • Accepted : 2020.10.15
  • Published : 2020.12.15
Download PDF
⟨ Previous Next ⟩

Abstract

The Committee on Dyslipidemia of Korean Pediatric and Adolescents of the Korean Society of Pediatric Endocrinology has newly developed evidence-based clinical practice guidelines for dyslipidemia in Korean children and adolescents. These guidelines were formulated with the Grading of Recommendations, which include both the strength of recommendations and the quality of evidence. In the absence of sufficient evidence, conclusions were based on expert opinion. These guidelines are based on the 2011 National Heart, Lung, and Blood Institute Guidelines, which focus on the prevention of cardiovascular disease in children and draw from a comprehensive review of evidence. These guidelines contain the definition of and screening process for dyslipidemia and introduce new dietary methods: the Cardiovascular Health Integrated Lifestyle Diet (CHILD)-1, the CHILD-2-low-density lipoprotein cholesterol, and the CHILD-2-triglyceride. Potential drug therapies for dyslipidemia along with their main effects and doses were also included.

Keywords

Acknowledgement

The authors greatly appreciate the members of Committee on Dyslipidemia of Korean Pediatric and Adolescents and the Korean Society for Pediatric Endocrinology for their support in developing and publishing these guidelines. This guideline is being simultaneously published in Annals of Pediatric Endocrinology & Metabolism and Clinical and Experimental Pediatrics.

References

  1. The Global Burden of Disease 2004 Update [Internet]. Geneva (Switzerland): World Health Organization; 2008 [cited 2020 May 3]. Available from: https://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf.
  2. Korea National Statistical Office. Annual report on the cause of death statistics, 2010 [Internet]. Daejeon (Korea): Statistics Korea; [cited 2020 May 3]. Available from: http://kostat.go.kr/portal/english/news/1/8/index.board?bmode=read&bSeq=&aSeq=250427&pageNo=1&rowNum=10&navCount=10&currPg=&sTarget=title.
  3. Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998;338:1650-6. https://doi.org/10.1056/NEJM199806043382302
  4. Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA 2000;284:311-8. https://doi.org/10.1001/jama.284.3.311
  5. Sone H, Tanaka S, Tanaka S, Iimuro S, Oida K, Yamasaki Y, et al. Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab 2011;96:3448-56. https://doi.org/10.1210/jc.2011-0622
  6. Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997;17:107-13. https://doi.org/10.1161/01.ATV.17.1.107
  7. Jee SH, Jang Y, Oh DJ, Oh BH, Lee SH, Park SW, et al. A coronary heart disease prediction model: the Korean Heart Study. BMJ Open 2014;4:e005025. https://doi.org/10.1136/bmjopen-2014-005025
  8. McGill HC Jr, McMahan CA, Zieske AW, Tracy RE, Malcom GT, Strong JP. Effects of nonlipid risk factors on atherosclerosis in youth with a favorable lipoprotein profile. Circulation 2001;103:1546-50. https://doi.org/10.1161/01.CIR.103.11.1546
  9. Ko M, Kim MT, Nam JJ. Assessing risk factors of coronary heart disease and its risk prediction among Korean adults: the 2001 Korea National Health and Nutrition Examination Survey. Int J Cardiol 2006;110:184-90 https://doi.org/10.1016/j.ijcard.2005.07.030
  10. Kim S, Moon S, Popkin BM. The nutrition transition in South Korea. Am J Clin Nutr 2000;71:44-53. https://doi.org/10.1093/ajcn/71.1.44
  11. Lauer RM, Lee J, Clarke WR. Factors affecting the relationship between childhood and adult cholesterol levels: the Muscatine Study. Pediatrics 1988;82:309-18.
  12. Kavey RE, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K, et al. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation 2003;107:1562-6. https://doi.org/10.1161/01.CIR.0000061521.15730.6E
  13. Raitakari OT, Juonala M, Kahonen M, Taittonen L, Laitinen T, MakiTorkko N, et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA 2003;290: 2277-83 https://doi.org/10.1001/jama.290.17.2277
  14. McGill HC Jr, McMahan CA, Malcom GT, Oalmann MC, Strong JP. Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. The PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Atheroscler Thromb Vasc Biol 1997; 17:95-106. https://doi.org/10.1161/01.ATV.17.1.95
  15. Kim SH, Ahn BC, Joung H, Park MJ. Lipid profiles and prevalence of dyslipidemia in Korean adolescents. Endocrinol Metab 2012;27:208-16. https://doi.org/10.3803/EnM.2012.27.3.208
  16. Yang S, Hwang JS, Park HK, Lee HS, Kim HS, Kim EY, et al. Serum lipid concentrations, prevalence of dyslipidemia, and percentage eligible for pharmacological treatment of Korean children and adolescents; data from the Korea National Health and Nutrition Examination Survey IV (2007-2009). PLoS One 2012;7:e49253. https://doi.org/10.1371/journal.pone.0049253
  17. Hickman TB, Briefel RR, Carroll MD, Rifkind BM, Cleeman JI, Maurer KR, et al. Distributions and trends of serum lipid levels among United States children and adolescents ages 4-19 years: data from the Third National Health and Nutrition Examination Survey. Prev Med 1998;27:879-90. https://doi.org/10.1006/pmed.1998.0376
  18. Ford ES, Li C, Zhao G, Mokdad AH. Concentrations of low-density lipoprotein cholesterol and total cholesterol among children and adolescents in the United States. Circulation 2009;119:1108-15. https://doi.org/10.1161/CIRCULATIONAHA.108.816769
  19. Shim YS, Baek JW, Kang MJ, Oh YJ, Yang S, Hwang IT. Reference values for the triglyceride to high-density lipoprotein cholesterol ratio and nonhigh-density lipoprotein cholesterol in Korean Children and Adolescents: the Korean National Health and Nutrition Examination Surveys 2007-2013. J Atheroscler Thromb 2016;23:1334-44. https://doi.org/10.5551/jat.35634
  20. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011;128(Suppl 5):S213-56. https://doi.org/10.1542/peds.2009-2107C
  21. Havel PJ. Dietary fructose: implications for dysregulation of energy homeostasis and lipid/carbohydrate metabolism. Nutr Rev 2005;63:133-57 https://doi.org/10.1111/j.1753-4887.2005.tb00132.x
  22. Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, et al. Summary of American Heart Association Diet and Lifestyle Recommendation revision 2006. Arterioscler Thromb Vasc Biol 2006; 26:2186-91 https://doi.org/10.1161/01.ATV.0000238352.25222.5e
  23. US Preventive Services Task Force. Screening for lipid disorders in children: US Preventive Services Task Force recommendation statement. Pediatrics 2007;120:e215-9. https://doi.org/10.1542/peds.2006-1812
  24. Haney EM, Huffman LH, Bougatsos C, Freeman M, Fu R, Steiner RD, et al. Screening for lipid disorders in children and adolescents [Internet]. Rockville: Agency for Healthcare Research and Quality; 2007 [cited 2020 May 3]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK33480/.
  25. Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet 1969;2:1380-2. https://doi.org/10.1016/S0140-6736(69)90930-1
  26. Srinivasan SR, Frontini MG, Xu J, Berenson GS. Utility of childhood non-high-density lipoprotein cholesterol levels in predicting adult dyslipidemia and other cardiovascular risks: the Bogalusa Heart Study. Pediatrics 2006;118:201-6. https://doi.org/10.1542/peds.2005-1856
  27. Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, Bush TL. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001;161:1413-9. https://doi.org/10.1001/archinte.161.11.1413
  28. Frontini MG, Srinivasan SR, Xu JH, Tang R, Bond MG, Berenson G. Utility of non-high-density lipoprotein cholesterol versus other lipoprotein measures in detecting subclinical atherosclerosis in young adults (The Bogalusa Heart Study). Am J Cardiol 2007;100:64-8. https://doi.org/10.1016/j.amjcard.2007.01.071
  29. Hong HR, Kim SU, Kang HS. Physical activity and metabolic syndrome in Korean children. Int J Sports Med 2009;30:677-83. https://doi.org/10.1055/s-0029-1224172
  30. Shin KO, Oh SY, Park HS. Empirically derived major dietary patterns and their associations with overweight in Korean preschool children. Br J Nutr 2007;98:416-21. https://doi.org/10.1017/S0007114507720226
  31. US department of agriculture; US Department of Health and Human Services. Dietary Guidelines for Americans, 2010. 7th ed. Washington, DC: US Government Printing Office, 2011.
  32. Becque MD, Katch VL, Rocchini AP, Marks CR, Moorehead C. Coronary risk incidence of obese adolescents: reduction by exercise plus diet intervention. Pediatrics 1988;81:605-12. https://doi.org/10.1542/peds.81.5.605
  33. McCrindle BW; American Heart Association Writing Group, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, et al. Summary of the American Heart Association's scientific statement on drug therapy of high-risk lipid abnormalities in children and adolescents. Arterioscler Thromb Vasc Biol 2007;27:982-5. https://doi.org/10.1161/ATVBAHA.107.143644
  34. McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 2007;115:1948-67. https://doi.org/10.1161/CIRCULATIONAHA.107.181946
  35. Daniels SR. Pediatric guidelines for dyslipidemia. J Clin Lipidol 2015;9(5 Suppl):S5-10. https://doi.org/10.1016/j.jacl.2015.03.105
  36. Manlhiot C, Larsson P, Gurofsky RC, Smith RW, Fillingham C, Clarizia NA, et al. Spectrum and management of hypertriglyceridemia among children in clinical practice. Pediatrics 2009;123:458-65. https://doi.org/10.1542/peds.2008-0367
  37. Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97:2969-89. https://doi.org/10.1210/jc.2011-3213
  38. Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Buller HR, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2004;292: 331-7. https://doi.org/10.1001/jama.292.3.331
  39. McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr 2003;143:74-80. https://doi.org/10.1016/S0022-3476(03)00186-0
  40. de Jongh S, Ose L, Szamosi T, Gagne C, Lambert M, Scott R, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 2002;106:2231-7. https://doi.org/10.1161/01.CIR.0000035247.42888.82
  41. Avis HJ, Vissers MN, Stein EA, Wijburg FA, Trip MD, Kastelein JJ, et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2007;27: 1803-10. https://doi.org/10.1161/ATVBAHA.107.145151
  42. Tonstad S, Knudtzon J, Sivertsen M, Refsum H, Ose L. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J Pediatr 1996;129:42-9. https://doi.org/10.1016/S0022-3476(96)70188-9
  43. Blagden MD, Chipperfield R. Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and 044106coronary heart disease. Curr Med Res Opin 2007;23:767-75. https://doi.org/10.1185/030079907X182059

Cited by

  1. Management of severe pediatric obesity vol.64, pp.6, 2020, https://doi.org/10.5124/jkma.2021.64.6.416